Lymphoma, Multiple Myeloma
Conditions
Keywords
peripheral blood stem cell mobilization, Mecapegfilgrastim, chemotherapy
Brief summary
This is a multicenter prospective study to evaluate the efficacy and safety of chemotherapy combined with a single dose of subcutaneous(SC) injection mecapegfilgrastim on day 2 or day 5 after chemotherapy for autologous peripheral blood stem cell (PBSC) mobilization in patients with multiple myeloma or lymphoma.
Detailed description
Subjects eligible for autologous stem-cell transplantation are randomized to receive a single dose of 12mg mecapegfilgrastim SC on day 2 or day 5 after chemotherapy for PBSC mobilization. According to the protocol, high-dose cyclophosphamide (50mg/kg or 2g/m2, for 2 days) is given to patients with MM, and high-dose etoposide (1.5-1.8g/m2, single dose ) is administered to patients with lymphoma. Apheresis is performed according to the standard institutional regulations. The primary point is to evaluate the percentage of successful mobilization, defined as the cumulative collection of ≥2×10\^6/kg CD34+ cells in three or fewer apheresis.
Interventions
DRUGEtoposide
Etoposide 1.5-1.8g/m2, single dose
DRUGCyclophosphamide
Cyclophosphamide 50mg/kg or 2g/m2, for 2 days
DRUGMecapegfilgrastim, day 2
Mecapegfilgrastim 12mg SC, on day 2 after chemotherapy
DRUGMecapegfilgrastim, day 5
Mecapegfilgrastim 12mg SC, on day 5 after chemotherapy
Sponsors
Jiangsu Hengrui Pharmaceutical Co., Ltd.
Institute of Hematology & Blood Diseases Hospital, China
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Lymphoma patients with ≤2 lines of prior therapy, patients with multiple myeloma with one line of therapy; 2. Patients who had achieved at least partial response (PR); 3. Patients who were eligible for autologous peripheral blood stem cell transplantation 4. Age≥18 and≤65 years; 5. Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 6. Patients who have an estimated life expectancy of more than three months 7. Fertile patients must be willing to use reliable contraception during the clinical study period and for 90 days after the last dose and have a negative serological pregnancy test within 72 hours prior to the first dose. 8. Patients must be able and willing to give written informed consent prior to any study-related procedures
Exclusion criteria
1. Patients who had previously attempted hematopoietic stem cell mobilization; 2. Patients who had undergone previous bone marrow transplantation; 3. Lymphoma patients with bone marrow involvement or patients with MM who had \>10% bone marrow involvement at screening ; 4. Patients with angina pectoris, myocardial infarction, coronary stent implantation, uncontrolled arrhythmias (atrial tachycardia, atrial fibrillation, persistent ventricular arrhythmias, etc.), cardiac insufficiency, Q-Tc interval \>500ms, left ventricular ejection fraction (EF)\<60%, or other heart diseases that the investigator considers unsuitable for hematopoietic stem cell mobilization or hematopoietic stem cell transplantation; 5. Patients with uncontrolled pulmonary infection; 6. Patients who had any of the following laboratory indicators: 1. White blood cell count(WBC)\<2.5×109/L； 2. Absolute neutrophil count(ANC)\<1.5×109/L； 3. Platelets count(PLT)\<80×109/L； 4. Creatinine \> 2.0 X ULN of the reference range or creatinine clearance ≤60ml/min 5. AST/ALT/Total bilirubin \> 2.5 X ULN； 7. Patients who have received any of the following treatments: 1. Patients who had been treated with more than 4 cycles of lenalidomide or received lenalidomide within 4 weeks prior to hematopoietic stem cell mobilization chemotherapy. 2. Patients who previously been treated with fludarabine or melphalan; 3. Patients who plan to receive radiation within 30 days after transplantation 4. Patients who had received radiation therapy in the pelvis 8. Patients allergic to Mecapegfilgrastim, pegylated granulocyte stimulating factor, granulocyte stimulating factor, or other formulations expressed by E. coli. 9. Patients who are pregnant or breastfeeding 10. Patients who are participating in other clinical studies or the interval of the last dose of prior study drug to the mobilization chemotherapy is less than 4 weeks (or 5 half-lives of the study drug); 11. Patients with other conditions unsuitable for this study according to the investigator's judgment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| percentage of successful mobilization | up to 28 days since the last subject were given mecapegfilgrastim | The percentage of subjects with ≥2×106 cell/kg CD34+ cells were collected. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| times to neutrophil and platelet engraftment | up to 1 year post-transplantation | times to neutrophil and platelet engraftment after autologous stem cell transplantation |
| the number of the total CD34+ cells | up to 28 days since the last subject were given mecapegfilgrastim | the number of the total CD34+ cells which were collected from each subject |
| the number of leukaphereses | up to 28 days since the last subject were given mecapegfilgrastim | the number of leukaphereses needed to collect ≥2×10\^6/kg CD34+ cells |
| Incidence of febrile neutropenia (FN) | up to 28 days since the last subject were given mecapegfilgrastim | incidence of FN during chemotherapy plus mecapegfilgrastim mobilization |
Countries
China
Contacts
Primary ContactWei Liu
Outcome results
None listed